Published: June 5, 2026 · Last updated: June 5, 2026
- As the national GLP-1 supply stabilized, the FDA clarified that large-scale compounding of these drugs is winding down (FDA, 2025)
- Compounded and unapproved GLP-1 products are not reviewed by the FDA for safety, effectiveness, or quality before sale (FDA, 2024)
- The FDA has flagged dosing errors, unapproved ingredients, fake products, and adverse events serious enough to require hospitalization (FDA, 2024)
For the past couple of years, the conversation about Ozempic and Wegovy has been all upside: dramatic weight loss, cultural ubiquity, and a scramble to get a prescription. What got far less attention is a quieter regulatory shift that directly affects the millions of people who turned to cheaper compounded or online versions to get around shortages and cost.
The short version is that the era of widely available compounded GLP-1 drugs is ending, and the FDA has been blunt about the safety risks of the unapproved versions still circulating. If you take one of these drugs or are considering it, this is the update worth understanding.
The Shift Most People Missed
Supply Stabilized, Rules Tightened: When brand-name GLP-1 drugs were in shortage, pharmacies were allowed to compound their own versions to fill the gap. That window was always temporary.
As the national supply began to stabilize, the FDA clarified its policies for compounders, signaling that the large-scale compounding of semaglutide and similar drugs is winding down (FDA, 2025).
For people who relied on a compounded version because it was cheaper or easier to find, this is a real change. The legal basis that allowed those products to flood the market is being pulled back, and the agency has even proposed excluding these drugs from the list compounders can make in bulk. In plain terms, the cheap workaround is closing.
Why Compounded Versions Are Risky
No Safety Net: The central issue is oversight. Unapproved versions of GLP-1 drugs do not go through the FDA's review for safety, effectiveness, and quality before they are marketed.
The agency has identified serious concerns with compounded semaglutide and tirzepatide, including dosing errors, the use of unapproved salt forms of the drug, and adverse events, some requiring hospitalization (FDA, 2024).
Dosing is a particular danger. These drugs are measured in very small amounts, and mistakes in mixing or self-injecting a compounded product can lead to overdoses that land people in the emergency room. The agency has also warned that some compounded products use unapproved salt forms of the drug that have not been shown to be safe or effective. Small errors in a powerful injectable are not minor.
The Counterfeit Problem
Fakes in the Supply Chain: Beyond legitimate compounding, the FDA has warned about outright fraudulent products marketed in the United States. This is the part of the story that gets almost no airtime.
The agency is aware of fake compounded semaglutide and tirzepatide that carry false information on their labels, in some cases listing compounding pharmacies that do not exist or did not make the product. Buying from an unfamiliar online seller raises the odds of getting one of these.
A low price and a slick website are not signs of safety. With injectable drugs, a counterfeit is not just ineffective; it can be contaminated or dosed unpredictably, and you have no way to verify what is actually in the vial. That uncertainty is the whole problem, because you are injecting the result directly into your body.
What This Means If You Buy Online
Cheaper Can Cost More: The appeal of online GLP-1 sellers has always been price and convenience. The regulatory shift and the safety warnings together change that calculation.
The FDA's guidance is straightforward: compounded drugs should generally only be used when a patient's needs cannot be met by an FDA-approved product, and prescriptions should be filled at state-licensed pharmacies. Telehealth sites that ship unbranded vials with little oversight fall outside that standard.
If you are currently using a compounded or imported version, this is a moment to reassess rather than assume nothing has changed. The market you bought into is being actively reshaped, and what was easy to obtain last year may be neither legal nor available in the same form now.
Talking to Your Doctor
Get the Real Thing the Right Way: The safest path to a GLP-1 drug is the least glamorous one: a prescription from your own clinician, filled at a licensed pharmacy, for an FDA-approved product.
That route gives you a known dose, quality control, and a professional monitoring side effects, which can include significant nausea and, rarely, more serious problems such as pancreatitis (Cleveland Clinic, 2024). It also means someone is checking whether the drug is appropriate for you at all, and that it fits with your other conditions and medications.
If cost is the barrier, that is a real conversation to have with your doctor, who can discuss approved options, savings programs, and alternatives. Cutting corners on an injectable medication is the wrong place to save money.
To your health,
Ageless Coach
Age Strong. Live Long.
Trusted Sources Behind This Article
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.
Frequently Asked Questions
Want one verified-science article like this every week?
Get Better Health, Weekly